Allergan settled claims of off-label marketing of its Botox pharmaceutical and other claims for a total of $600 million. The government accused Allergan of recommending Botox for unapproved uses including headache, pain, spasticity and juvenile cerebral palsy. As part of the settlement, Allergan also pleaded guilty to misdemeanor charge of misbranding, or inadequate labeling of products for intended uses. Allergan is also required under the settlement to hire and pay for a third-party to monitor is compliance efforts for the next five years.
For more information see: http://online.wsj.com/article/SB10001424052748703882304575465371767239834.html?mod=googlenews_wsj
